GlassScriptPhysician profile
Aniesa Slack
NPI 1730506684
$394.33
in general payments reported to CMS, 2019-2025
15 companies · $91.06 in 2025
The $91.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.81 · 2022: $234 · 2024: $15.81 · 2025: $91.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $106.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $62.60 | 2022 | |
| Lilly USA, LLC | $41.78 | 2021-2022 | |
| Amgen INC. | $33.92 | 2022 | |
| Novo Nordisk INC | $33.77 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $31.39 | 2025 | Zoryve |
| Mylan Specialty L.P. | $30.40 | 2022 | |
| Biogen, INC. | $29.30 | 2025 | Zurzuvae |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.12 | 2022 | |
| Viatris Specialty LLC | $15.19 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $15.18 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $14.96 | 2022 | |
| Endo Pharmaceuticals INC. | $14.69 | 2021 | |
| Neurelis, INC. | $14.59 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aniesa Slack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.